2D DIGE of the cerebrospinal fluid proteome in neurological diseases

被引：27
作者：
Tumani, Hayrettin [1 ]
Lehmensiek, Vera
Lehnert, Stefan [1 ]
Otto, Markus [1 ]
Brettschneider, Johannes
机构：
[1] Univ Ulm, Dept Neurol, IZKF, D-89081 Ulm, Germany
来源：
EXPERT REVIEW OF PROTEOMICS | 2010年 / 7卷 / 01期
关键词：
2D DIGE; biomarker; cerebrospinal fluid; neurological disease; proteome; DIFFERENTIAL GEL-ELECTROPHORESIS; MASS-SPECTROMETRY; MINIMUM INFORMATION; CSF; IDENTIFICATION; BIOMARKERS; DIAGNOSIS; BARRIER; DYSFUNCTION; UTILITY;
D O I：
10.1586/EPR.09.99
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
2D DIGE is a promising approach to comparative proteome analysis known for a high sensitivity and high reproducibility compared with classical 2DE techniques. It offers new possibilities for the detection of cerebrospinal fluid (CSF) biomarkers in neurological diseases, such as dementia, amyotrophic lateral sclerosis or multiple sclerosis. We review the first studies using 2D DIGE for analysis of the CSF proteome in neurological diseases and discuss advantages, as well as drawbacks, of the methodological approach with special emphasis on CSF-related aspects.
引用
收藏
页码：29 / 38
页数：10
相关论文
共 52 条
[1]  
Ahmed FE, 2009, EXPERT REV PROTEOMIC, V6, P171, DOI [10.1586/epr.09.4, 10.1586/EPR.09.4]
[2]   Utility of mass spectrometry for proteome analysis: part I. Conceptual and experimental approaches [J].
Ahmed, Farid E. .
EXPERT REVIEW OF PROTEOMICS, 2008, 5 (06) :841-864
[3]   Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].
Andreasen, N ;
Vanmechelen, E ;
Van de Voorde, A ;
Davidsson, P ;
Hesse, C ;
Tarvonen, S ;
Räihä, I ;
Sourander, L ;
Winblad, B ;
Blennow, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305
[4]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[5]   The synergy of elemental and biomolecular mass spectrometry: new analytical strategies in life sciences [J].
Becker, J. Sabine ;
Jakubowski, Norbert .
CHEMICAL SOCIETY REVIEWS, 2009, 38 (07) :1969-1983
[6]   Development of biomarkers in multiple sclerosis [J].
Bielekova, B ;
Martin, R .
BRAIN, 2004, 127 :1463-1478
[7]  
Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub3, 10.1002/14651858.CD001190.pub2]
[8]  
BLENNOW K, 1993, ACTA NEUROL SCAND, V88, P221
[9]   The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration [J].
Bossuyt, PM ;
Reitsma, JB ;
Bruns, DE ;
Gatsonis, CA ;
Glasziou, PP ;
Irwig, LM ;
Moher, D ;
Rennie, D ;
de Vet, HCW ;
Lijmer, JG .
CLINICAL CHEMISTRY, 2003, 49 (01) :7-18
[10]   Minimum information about a microarray experiment (MIAME) - toward standards for microarray data [J].
Brazma, A ;
Hingamp, P ;
Quackenbush, J ;
Sherlock, G ;
Spellman, P ;
Stoeckert, C ;
Aach, J ;
Ansorge, W ;
Ball, CA ;
Causton, HC ;
Gaasterland, T ;
Glenisson, P ;
Holstege, FCP ;
Kim, IF ;
Markowitz, V ;
Matese, JC ;
Parkinson, H ;
Robinson, A ;
Sarkans, U ;
Schulze-Kremer, S ;
Stewart, J ;
Taylor, R ;
Vilo, J ;
Vingron, M .
NATURE GENETICS, 2001, 29 (04) :365-371
123456